Format

Send to

Choose Destination
Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15.

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Author information

1
Department of Radiation Oncology, University of Wuerzburg, Germany; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.
2
Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Germany.
3
Department of Radiation Oncology, Barmherzige Brüder, Regensburg, Germany.
4
Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, University Medicine Rostock, Germany.
5
Department of Radiation Oncology, UKSH Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
6
Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany.
7
Department of Radiation Oncology, Allgemeines Krankenhaus Wien, Vienna, Austria.
8
Department of Radiation Oncology, Technical University Munich, Germany.
9
Department of Radiation Oncology, Universitätsklinikum Münster, Germany.
10
Department of Radiation Oncology, LMU München, Munich, Germany.
11
Department of Radiation Oncology, Universitätsklinikum Magdeburg, Germany.
12
Department of Radiotherapy and Special Oncology, Medical School Hannover, Germany.
13
Department of Radiation Oncology, Universitätsklinikum Aachen, Germany.
14
Department of Radiation Oncology, Universitätsklinikum Frankfurt am Main, Germany.
15
Department of Radiation Oncology, Klinikum Augsburg, Germany.
16
Department of Radiation Oncology, Helios Klinikum Berlin Buch, Germany.
17
Department of Radiation Oncology, Medical Faculty and University Hospital C.G. Carus, Technische Universität Dresden, Germany.
18
Department of Radiation Oncology Universitätsklinikum Freiburg, Germany.
19
Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Austria.
20
Department of Radiation Oncology, Universitätsklinikum Eppendorf, Hamburg, Germany.
21
Department of Radiation Oncology, Friedrich Alexander University of Erlangen-Nurenberg, Germany.
22
Department of Radiation Oncology, Heidelberg University Hospital, Germany.
23
Department of Radiation Oncology, University Hospital Jena, Germany.
24
Department of Radiotherapy and Radiation Oncology, Pilipps-University Marburg, Germany.
25
Department of Radiation Oncology, University of Wuerzburg, Germany.

Abstract

BACKGROUND AND PURPOSE:

To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.

MATERIALS AND METHODS:

A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.

RESULTS:

After median follow-up of 19 months and 16 months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176 Gy (151-223) and 160 Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.

CONCLUSIONS:

Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.

KEYWORDS:

Lung metastases; Non-small cell lung cancer; Stereotactic body radiotherapy; Tumor control probability

PMID:
26385265
DOI:
10.1016/j.radonc.2015.09.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center